Get the Stockscreener App
61.15
0.50%
-0.31
After Hours:
61.02
-0.13
-0.21%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $61.15, with a volume of 9.64M.
It is down -0.50% in the last 24 hours and down -9.62% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$61.46
Open:
$60.66
24h Volume:
9.64M
Relative Volume:
0.89
Market Cap:
$124.91B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
17.16
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-2.72%
1M Performance:
-9.62%
6M Performance:
+2.60%
1Y Performance:
+33.72%
1-Day Range:
$60.24
$61.24
1-Week Range:
$60.24
$64.13
52-Week Range:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
61.15 | 128.41B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale - currently.att.yahoo.com
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights - GlobeNewswire Inc.
United Therapeutics’ legal victory; BMS’ Camzyos approved for kids - Endpoints News
Bristol Myers Squibb (BMY) Boosts Champions in Care Initiative w - GuruFocus
Healthcare professionals can nominate nonprofits for Bristol Myers Squibb's $1 million grants - Stock Titan
Children with this heart condition have one FDA-approved option: Bristol Myers Squibb's CAMZYOS. - Stock Titan
FDA Approves Bristol Myers Squibb's Camzyos for Pediatric Obstru - GuruFocus
Jamaal Sebastian-Barnes Elevated to Senior Vice President, Head of HR – Research and Development at Bristol Myers Squibb - hrtoday.in
FDA Approves Bristol Myers' Camzyos for Pediatric Obstructive Hy - GuruFocus
Portal Innovations CEO John Flavin expects more pharma acquisitions of Houston companies - The Business Journals
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)Market Insights, Epidemiology, and Market Forecast - GlobeNewswire Inc.
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb (BMY) Faces Liver Injury Concerns in Admilp - GuruFocus
Why Are ZENBEXUS Data Putting Bristol-Myers (NYSE:BMY) in Focus? - Kalkine Media
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation - The Motley Fool
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb awarded honour for being first employer to gain triple-region Menopause Friendly Accreditation - hrnews.co.uk
Bristol-Myers Squibb Co (BRM.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? - Insider Monkey
Bristol Myers Squibb posts first Phase 3 results for ZENBEXUS combo in multiple myeloma - app.dealroom.co
Bristol Myers Squibb’s Zenbexus shows improved response rates - Investing.com
Bristol Myers Squibb’s Zenbexus shows improved response rates By Investing.com - Investing.com Canada
Bristol Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Zacks Research Brokers Increase Earnings Estimates for BMY - MarketBeat
Bristol Myers Squibb Company (NYSE:BMY) Stock Has Consensus Target Price of $67.06 - MarketBeat
Can Recent Traction With Key Drugs and Pipeline Progress Boost BMY? - TradingView
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? - The Motley Fool
Bristol Myers Squibb announces 265 additional job cuts - medwatch.com
Engineers Gate Manager LP Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb To Cut 265 More Jobs Tied To Its New Jersey Operations - communitynews.org
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Goldman Sachs reiterates Bristol-Myers Squibb stock Neutral rating - Investing.com
Goldman Sachs reiterates Bristol-Myers Squibb stock Neutral rating By Investing.com - Investing.com Canada
How AI Is Accelerating Drug Discovery And Patient Health At Bristol Myers Squibb - Forbes
Layoff Tracker: Novo workforce down 13,000 - BioSpace
Bristol Myers Squibb stock slips at the close - AD HOC NEWS
Bristol Myers cuts another 265 jobs tied to New Jersey headquarters - Fierce Pharma
State Street Corp Has $6.09 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Pharmaceutical giant to lay off 265 N.J. workers in 3rd wave of job cuts this year - NJ.com
Bristol Myers Squibb invests $2.3B in Houston campus - scanx.trade
Bristol Myers Squibb stock gains support as 2026 outlook and consensus improve - ad-hoc-news.de
Bristol-Myers Squibb (BMY) Stock Analysis: A Healthcare Giant With 5.79% Upside Potential - DirectorsTalk Interviews
Bristol Myers Squibb stock heads into the open after a 0.8 percent gain - AD HOC NEWS
Bristol-Myers Squibb stock heads into the open after a 0.8% gain - AD HOC NEWS
Bristol-Myers Squibb (NYSE:BMY): Its history spans 16 decades, but the next few years could be the most important ever! - Stocks Down Under
Bristol Myers Squibb stops work on Orum's ORM-6151 after Phase 1 data - app.dealroom.co
Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder - The Motley Fool
Bristol Myers Squibb stock holds near USD 63 as investors look to October 29 results - AD HOC NEWS
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):